Lisocabtagene maraleucel (Breyanzi®) for the treatment of adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy

Marschik, T. and Rothschedl, E. and Geiger-Gritsch, S. (2025): Lisocabtagene maraleucel (Breyanzi®) for the treatment of adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy. Fact Sheet Nr. 212.

Preview

PDF - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. GSview, Xpdf oder Adobe Acrobat Reader
461kB

Item Type:	Horizon Scanning of Medicines
Subjects:	QV Pharmacology, toxicology, pharmacy > QV 60-370 Pharmacology QZ Pathology > QZ 200-380 Neoplasms.Cysts WB Practice of medicine > WB 300-962 Therapeutics WH Hemic and lymphatic systems
Language:	English
Series Name:	Fact Sheet Nr. 212
Deposited on:	18 Nov 2025 14:29
Last Modified:	18 Nov 2025 14:29

Repository Staff Only: item control page